

# SAMSRITA LABS LIMITED

(Formerly Known as DR Habeebullah Life Sciences Limited)

To,

Date: 12.08.2024

1. BSE Limited P.J. Towers, Dalal Street, Mumbai-400 001	2. Metropolitan Stock Exchange of India Limited 205(A), 2 <sup>nd</sup> Floor, Piramal Agastya Corporate Park, Kamani Junction, LBS Road, Kurla (West), Mumbai-400 070
--	--

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held on 12.08.2024 under Regulation 33 and 30 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.**

**Unit: Samsrita Labs Limited (Formerly known as Dr Habeebullah Life Sciences Limited)  
(Scrip Code: 539267/ SAMSRITA)**

With reference to the subject cited above, this is to inform the Exchanges that at the meeting of the Board of Directors of Samsrita Labs Limited (formerly known as Dr Habeebullah Life Sciences Limited) held on Monday, 12<sup>th</sup> August, 2024 at 03:30 p.m. at the registered office of the Company at 6-3-354/13/B2, Flat. No. B2, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad-500082, Telangana, the following were considered and approved:

1. Un-audited financial results for the quarter ended 30.06.2024. **(Enclosed)**
2. Limited Review Report for the quarter ended 30.06.2024 **(Enclosed)**.
3. Reappointment of M/s S.S Reddy & Associates as Secretarial Auditor for Financial year 2024-25. **(Brief Profile Enclosed as Annexure I)**
4. 28<sup>th</sup> Director's Report for the Financial Year 2023-24 and Notice for convening 28<sup>th</sup> Annual General Meeting (AGM) for the financial year 2023-24.
5. 28<sup>th</sup> Annual General Meeting is scheduled to be held on Saturday, 21.09.2024 at 11:00 A.M. through Video Conference or Other Audio Visual Means (OAVM).

The meeting concluded at 4.45 p.m.

This is for the information and records of the Exchanges, please.

Thanking you.

Yours sincerely,

For Samsrita Labs Limited  
(Formerly known as Dr Habeebullah Life Sciences Limited)

*K. Navendra Kumar*  
K.N.V. Narendra Kumar  
Whole-time Director & CFO  
DIN: 09223904



Encl: as above

Regd.Off & Corp Off: 6-3-354/13/B2, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad.500082.  
CIN No: L85110TG1996PLC09918. Email: [info@drhlsl.com](mailto:info@drhlsl.com), [pcproductsindia@gmail.com](mailto:pcproductsindia@gmail.com), [cs@drhlsl.com](mailto:cs@drhlsl.com)  
Contact No.9490424639, Website: [www.drhlsl.com](http://www.drhlsl.com)

# SAMSRITA LABS LIMITED

(Formerly Known as DR Habeebullah Life Sciences Limited)

## Annexure I

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/ 120 dated 11th July, 2023]

S.no.	Particulars	Details
1	Name	M/s S.S Reddy and Associates
2	Reason for change viz. appointment, resignation	Re-appointment of M/s.S.S Reddy and Associates as Secretarial Auditors for FY 2024-25
3	Date of reappointment and term of re-appointment	For the Financial Year 2024-25
4	Brief Profile (in case of appointment)	M/s. S.S. Reddy & Associates was established as a proprietorship firm in the year 2007 at Hyderabad by Mr. S. Sarweswar Reddy. Mr. Reddy is a former Executive Director of Hyderabad Stock Exchange (HSE) and served in various capacities at HSE for about 12 years. He is also a member of Capital Markets Team of The Federation of Telangana Chambers of Commerce and Industry (FTCCI). Mr. Reddy is a panel member of NSE and MCX Investor Grievance Resolution. Currently he is serving as an Independent Director on the Board of 2 Listed Companies namely, Sigachi Industries Limited and Bondada Engineering Limited Mr.
5	Relationship with other directors (in case of appointment)	NA

Regd.Off & Corp Off: 6-3-354/13/B2, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad.500082.  
CIN No: L85110TG1996PLC09918. Email: [info@drhsl.com](mailto:info@drhsl.com), [pcproductsindia@gmail.com](mailto:pcproductsindia@gmail.com), [cs@drhsl.com](mailto:cs@drhsl.com)  
Contact No.9490424639, Website: [www.drhsl.com](http://www.drhsl.com)

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER I ENDED 30TH JUNE, 2024**

		(INR In Lakhs)			
		Quarter Ended			Previous Year
		3 Months Ended 30/6/2024	Preceding 3 Months Ended 31/03/2024	Corresponding 3 months ended in previous year 30/06/2023	Ended 31- 03-2024
		UnAudited	Audited	UnAudited	Audited
<b>I</b>	<b>Revenue from Operations</b>	-	-	-	-
<b>II</b>	<b>Other Income</b>	-	-	-	-
<b>III</b>	<b>Total Revenue (I+II)</b>	-	-	-	-
<b>IV</b>	<b>Expenses</b>				
	Purchases	-	-	-	-
	Cost of Material Consumed	-	-	-	-
	Employee benefits expense	2.76	4.26	2.76	12.54
	Depreciation and Amortisation expense	0.03	0.12	0.05	0.24
	Other Expenses	5.92	2.64	5.80	12.21
	<b>Total Expenses</b>	<b>8.72</b>	<b>7.02</b>	<b>8.61</b>	<b>24.99</b>
<b>V</b>	<b>Profit/(Loss) from before Exceptional Items and tax (I-IV)</b>	<b>(8.72)</b>	<b>(7.02)</b>	<b>(8.61)</b>	<b>(24.99)</b>
<b>VI</b>	<b>Exceptional Items</b>	-	-	-	-
<b>VII</b>	<b>Profit/(Loss) before tax (V-VI)</b>	<b>(8.72)</b>	<b>(7.02)</b>	<b>(8.61)</b>	<b>(24.99)</b>
<b>VIII</b>	<b>Tax Expense:</b>				
	Current Tax	-	-	-	-
	Deferred Tax	-	-	-	-
<b>IX</b>	<b>Profit/ (Loss) for the period from Continuing operations (VII-VIII)</b>	<b>(8.72)</b>	<b>(7.02)</b>	<b>(8.61)</b>	<b>(24.99)</b>
<b>X</b>	<b>Profit/ (Loss) from discontinuing operations</b>	-	-	-	-
<b>XI</b>	<b>Tax Expense of discontinuing operations</b>	-	-	-	-
<b>XII</b>	<b>Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)</b>	-	-	-	-
<b>XIII</b>	<b>Profit/ (Loss) for the period (IX+XII)</b>	<b>(8.72)</b>	<b>(7.02)</b>	<b>(8.61)</b>	<b>(24.99)</b>
<b>XIV</b>	<b>Other Comprehensive Income</b>				
	A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss	-	-	-	-
	(B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to	-	-	-	-
<b>XV</b>	<b>period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)</b>	<b>(8.72)</b>	<b>(7.02)</b>	<b>(8.61)</b>	<b>(24.99)</b>
<b>XVI</b>	<b>Comprehensive Income attributable to Non Controlling Interest</b>	-	-	-	-
<b>XVII</b>	<b>Comprehensive Income attributable to Owners of the company</b>	<b>(8.72)</b>	<b>(7.02)</b>	<b>(8.61)</b>	<b>(24.99)</b>
<b>XVIII</b>	<b>Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)</b>				
	1) Basic	(0.06)	(0.05)	(0.06)	(0.17)
	2) Diluted	(0.06)	(0.05)	(0.06)	(0.17)
<b>XIX</b>	<b>Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)</b>				
	1) Basic	-	-	-	-
	2) Diluted	-	-	-	-
<b>XX</b>	<b>Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)</b>				
	1) Basic	(0.06)	(0.05)	(0.06)	(0.17)
	2) Diluted	(0.06)	(0.05)	(0.06)	(0.17)
<b>XXI</b>	<b>Paid Up Equity Share Capital (Face Value of INR 10/- per share)</b>	<b>1,480.87</b>	<b>1,480.87</b>	<b>1,480.87</b>	<b>1,480.87</b>

**Notes:**

1. The above unaudited financial results for the quarter ended 30th June 2024 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Monday 12th August 2024.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
4. The Previous year's/quarter's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

For SAMSRITA LABS LIMITED

*K. Narendra Kumar*  
K N.V.Narendra Kumar

Whole time Director & CFO (DIN 09223904)



Place : Hyderabad  
Date: 12/08/2024



**Independent Auditor's Review Report on unaudited Quarterly Financial results of Samsrita labs Limited (Formerly known as Dr Habeebullah Life Sciences Limited) Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
The Board of Directors,  
Samsrita Labs Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Samsrita Labs Limited ("the Company") for the quarter ended June 30, 2024 and year to date results for the period April 01, 2024 to June 30, 2024 ("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

**MUMBAI OFFICE :**

AKT House, Plot No. C1 B 4/32,  
Opp. Artist Village Bus Stand,  
Near Arenja Complex, Sec. 8,  
CBD Belapur, Mumbai - 400 614

**KOLKATA OFFICE :**

Octavius Building, 1st Floor,  
15C, Hemant Bassu Sarani,  
Opp. Great Eastern Hotel,  
Kolkata, West Bengal - 700 001

**DELHI OFFICE :**

# 204, Pearls Best Heights - 2  
Netaji Subhash Place,  
Pitampura, Delhi - 110 034.



**MGR & CO**  
CHARTERED ACCOUNTANTS

**HYDERABAD OFFICE :**

Flat No. 101, Suranjana Empire Estates,  
Opp. Union Bank of India, Dwarakapuri Colony,  
Panjagutta, Hyderabad - 500 082.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MGR & CO  
Chartered Accountants  
FRN:012787S

*M.G Rao*

M.G Rao  
Partner

M.No.029893

UDIN: 24029893BKACSZ1247



Place: Hyderabad

Date: 12/08/2024

**MUMBAI OFFICE :**

AKT House, Plot No. C1 B 4/32,  
Opp. Artist Village Bus Stand,  
Near Arenja Complex, Sec. 8,  
CBD Belapur, Mumbai - 400 614

**KOLKATA OFFICE :**

Octavius Building, 1st Floor,  
15C, Hemant Bassu Sarani,  
Opp. Great Eastern Hotel,  
Kolkata, West Bengal - 700 001

**DELHI OFFICE :**

# 204, Pearls Best Heights - 2  
Netaji Subhash Place,  
Pitampura, Delhi - 110 034.